Latest News

Data showed that talquetamab combined with daratumumab, with or without pomalidomide, significantly improved PFS, OS, response rates, and MRD negativity.

The FDA approved Rextovy, a 4-mg over-the-counter naloxone nasal spray, expanding public access to a life-saving opioid overdose reversal medication and increasing the availability of nonprescription treatment options.

The indication is for complicated urinary tract infections (UTIs) caused by several susceptible microorganisms in adults who have limited or no alternative oral treatment options.

Identifying high-risk patients, optimizing lipid-lowering therapy, and helping patients achieve evidence-based targets remain critical to improving cardiovascular outcomes.

The findings add to a growing body of evidence supporting metformin's role as a preventive strategy against postacute sequelae of COVID-19.

The ADA Scientific Sessions highlighted important advances across the diabetes treatment landscape.

A candid midlife reckoning in modern pharmacy care: Reclaim purpose, question the system, and reconnect work to meaning, patient impact, and wholehearted living.

When pharmacists and clinical decision support software work in tandem, the result is a powerful safety net that catches medication errors before they reach patients.

While overall drug shortages declined in 2025, USP findings suggest that longstanding supply chain vulnerabilities continue to fuel persistent shortages across multiple therapeutic areas.

Proactive, multidisciplinary strategies for managing drug shortages.

Pharmacists are increasingly positioned to answer questions and address patient interests as peptide therapies expand rapidly across clinical settings.

The integrated CGM is now indicated for individuals 2 years and older who do not use insulin.

At ACTHIV 2026, Jaimee Colvin, MSN, APRN, FNP-C, outlined how provider knowledge gaps, entrenched stigma, and a lack of culturally representative outreach continue to drive the PrEP disparity among cisgender Black and Brown women.

Approval of teplizumab-mzwv in patients aged 8 to 17 years makes it the first disease-modifying therapy for children newly diagnosed with stage 3 type 1 diabetes.

FDA clears teclistamab plus daratumumab after first relapse, delivering striking PFS gains—plus practical tips to manage CRS, ICANS, and infections.

Data presented at EHA 2026 showed that epcoritamab significantly improved progression-free survival and complete response rates compared with standard chemoimmunotherapy in patients with relapsed or refractory (RR) large B-cell lymphoma (LBCL).

This year’s guide, compiled from a national survey of 1700 practicing pharmacists, identifies the top recommended brands across 145 product categories, ranging from pediatric care to pain relief.

Korean and Asian manufacturers have used bemotrizinol widely in sunscreen formulations for many years.

Long-term data show that frontline zanubrutinib significantly improved second progression-free survival (PFS2) and preserved the effectiveness of subsequent BCL2 inhibitor–based therapies compared with bendamustine-rituximab in treatment-naive CLL/SLL.

Specialty pharmacy technicians address barriers in oral anticancer therapy and transitions of care through improved care coordination and therapy access.

Inlexzo Gemcitabine Intravesical System delivers sustained therapy for BCG-unresponsive NMIBC, raising complete response and avoiding cystectomy.